A Phase III Multicenter, Randomized, Open-Label Trial Evaluating High Dose Melphalan Plus Holmium-166-DOTMP Versus High Dose Melphalan Alone When Given In Conjuction With Peripheral Blood Stem Cell Transplantation In Patients With Multiple Myeloma
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Melphalan (Primary) ; Holmium-166-DOTMP
- Indications Multiple myeloma
- Focus Therapeutic Use
- 21 Sep 2010 Biomarkers information updated
- 08 Apr 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 08 Apr 2009 Actual end date added Sep 2001 as reported by ClinicalTrials.gov.